» Articles » PMID: 34140600

Transmitted HIV Drug Resistance and Subtype Patterns Among Blood Donors in Poland

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 18
PMID 34140600
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Surveillance on the HIV molecular variability, risk of drug resistance transmission and evolution of novel viral variants among blood donors remains an understudied aspect of hemovigilance. This nationwide study analyses patterns of HIV diversity and transmitted resistance mutations. Study included 185 samples from the first time and repeat blood donors with HIV infection identified by molecular assay. HIV protease, reverse transcriptase and integrase were sequenced using population methods. Drug resistance mutation (DRM) patterns were analyzed based on the Stanford Interpretation Algorithm and standardized lists of transmitted mutations. Phylogeny was used to investigate subtyping, clustering and recombination patterns. HIV-1 subtype B (89.2%) followed by subtype A6 (7.6%) were predominant, while in three (1.6%) cases, novel recombinant B/A6 variants were identified. Non-B variants were more common among repeat donors (14.5%) compared to the first time ones (1.8%), p = 0.011, with higher frequency (9.9%) of A6 variant in the repeat donor group, p = 0.04. Major NRTI DRMs were observed in 3.8%, NNRTI and PI in 0.6% and INSTI 1.1% of cases. Additionally, E157Q polymorphism was observed in 9.8% and L74I in 11.5% of integrase sequences. Transmission of drug resistance among blood donors remains infrequent. Subtype patters increase in complexity with emergence of novel intersubtype A6B recombinants.

Citing Articles

Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability.

Mielczak K, Serwin K, Urbanska A, Aksak-Was B, Karasinska-Cieslak M, Mularska E Viruses. 2024; 16(10).

PMID: 39459930 PMC: 11512334. DOI: 10.3390/v16101597.


HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon.

Mangala C, Takou D, Maulot-Bangola D, Beloumou G, Rebienot Pellegrin O, Sosso S PLoS One. 2024; 19(9):e0305935.

PMID: 39226273 PMC: 11371224. DOI: 10.1371/journal.pone.0305935.


Human Immunodeficiency Virus Type-1 Genetic Diversity and Drugs Resistance Mutations among People Living with HIV in Karachi, Pakistan.

Rashid A, Kang L, Yi F, Chu Q, Shah S, Mahmood S Viruses. 2024; 16(6).

PMID: 38932254 PMC: 11209141. DOI: 10.3390/v16060962.

References
1.
Laperche S, Tiberghien P, Roche-Longin C, Pillonel J . Fifteen years of Nucleic Acid Testing in France: Results and lessons. Transfus Clin Biol. 2017; 24(3):182-188. DOI: 10.1016/j.tracli.2017.06.020. View

2.
Bes M, Piron M, Casamitjana N, Gregori J, Esteban J, Ribera E . Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014). Transfusion. 2017; 57(9):2164-2173. DOI: 10.1111/trf.14195. View

3.
Zeng P, Liu Y, He M, Wang J, Keating S, Mao W . The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014. PLoS One. 2017; 12(6):e0179328. PMC: 5473534. DOI: 10.1371/journal.pone.0179328. View

4.
Crispim M, Reis M, Fraiji N, Bello G, Stefani M . Detection of human immunodeficiency virus Type 1 phylogenetic clusters with multidrug resistance mutations among 2011 to 2017 blood donors from the highly endemic Northern Brazilian Amazon. Transfusion. 2019; 59(8):2593-2601. DOI: 10.1111/trf.15347. View

5.
Rosinska M, Marzec-Bogustawska A, Janiec J, Smolen-Dzirba J, Wasik T, Gniewosz J . High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. AIDS Res Hum Retroviruses. 2013; 29(5):805-13. PMC: 3636578. DOI: 10.1089/aid.2012.0314. View